Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: Our current research paper in CLL published in Blood Advances was presented. Further goals were discussed. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: To learn how to calculate EFS,OS, TRM, how to create Kaplan Meier curves and CI curves. The difference between CI and Kapolan Meier was discussed. Corresponding literature from ALPWP EBMT is provided. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: To learn the differences between RIC, RTC, MAC, NMA, etc. Corresponding literature is provided. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: To learn how to deceide whether we should get an older person to transplant. Literature and cases are presented. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: To understand the structure of donor registries. Learn corresponding terminology. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal:To learn about Bite, inotuzumab and CART therapies. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: Which graft is better to use in haplo PTCY transplant? Dr Liga presented the current literature. We deceide the following policy CR-1 BM, advanced disease PBSC. Presenter: Dr Liga Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: An overview of the haplo PTCY platform. Presenter: Dr Liga. Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: Principles of Donor selection. Quiz and examples were shown. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Triantafyllou  
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: to get an overview of current cellular therapies and learn where we stand. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou
Καταχωρήθηκε: Σάββατο 02 Σεπ 2017
a reent  study publisghed at LEukemia confirms the role of upfront ASCT in MM. Upfornt autolgous is the standrd of care in MM Presenter: Spyridonidis Patriciapnts: all medical staff
Καταχωρήθηκε: Σάββατο 02 Σεπ 2017
Καταχωρήθηκε: Παρασκευή 01 Σεπ 2017
The FDA approved tisagenlecleucel (Kymriah) for certain paediatric and young adult patients with B-cell acute lymphoblastic leukaemia (ALL). The cell-based gene therapy is approved in the United States for the treatment of patients up to 25 years of age with B-cell precursor ALL that...
Καταχωρήθηκε: Παρασκευή 25 Αύγ 2017
Combined use of global and targeted analyses allows the cytogenetic classification of 88% of adult patients with Ph-negative BCP-ALL. • In GRAALL trials, t(4;11)/KMT2A-AFF1 and t(v;14q32)/IGH are the two cytogenetic anomalies significantly associated with a worse outcome. Combined use of global and targeted analyses allows the cytogenetic...
Καταχωρήθηκε: Κυριακή 20 Αύγ 2017
We often see such patients and the question is raised whether transplant could help these poatients. A rertrospetive analysis from the Italian transplant centers tries to answer this. There ia an accompayiong editorial on this analysis. Presenter: Spyridonidis participants: all medical staff 
Καταχωρήθηκε: Τρίτη 15 Αύγ 2017
Venetoclax Gets Breakthrough-Therapy Designation for AML At 12-month follow-up, the overall response rate was 44 percent (complete remission, n=4; complete remission without complete marrow recovery, n=4; resistant disease, n=8; death before evaluation, n=2). FDA Approves Combination Daunorubicin and Cytarabine for High-Risk AML The drug was approved based on...
Καταχωρήθηκε: Κυριακή 13 Αύγ 2017
Wediscussed the incidence and diagnosis of IDH mutations in AML. The new approved drug may prove very helpful for these patients Presenter: Spyridonidis Participants: all medical staff   The US Food and Drug Administration (FDA) has approved enasidenib (Idhifa) for the treatment of relapsed or refractory...
Καταχωρήθηκε: Τετάρτη 12 Ιούλ 2017
Extended analysis of the fiorst randomized ATG trial in BMT. Presenter: Spyridonidis Participants: All medical staff
Καταχωρήθηκε: Τετάρτη 05 Ιούλ 2017
Excellent paper by John Dicks group published in Nature. The study identifies the reasosn  why some aptrients relapse also amny years after chemothertpay or allogheneic BMT. Presenter: Spyridonidis Participants: All medical staff
Καταχωρήθηκε: Πέμπτη 22 Ιούν 2017
An intersting study showed a correaltion between CHIP and atherpscleorosis. We discussed the CHIP. Presenter Spyridonidis Participants: all medical staff
Βρέθηκαν 269 αποτελέσματα. Σελίδα 9 από 14
Σελίδα << < [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] > >>
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2021 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας